BEAM

Beam Therapeutics

Halal Rating :
Uncomfortable
Last Price $29.03 Last updated:
Market Cap $2.2b
7D Change 3.94%
1 Year Change 3.42%
Company Overview Use of Interest Company Impact Justification for our Halal Rating Recent News

Company Overview

Industries
  • Manufacturing
  • Pharmaceutical Products
  • Biological Products
  • Except Diagnostic Substances
Exchange NASDAQ
Next Earnings Date Nov. 6, 2024

Beam Therapeutics Inc. is a biotechnology company focused on developing precision genetic medicines through its proprietary base editing technology. The company's technology enables precise and permanent changes to DNA and RNA sequences to treat genetic diseases. Beam's approach uses CRISPR technology in a novel way that allows for the targeted editing of individual DNA bases without cutting the DNA strand.

The company is primarily in research and development phase, working on treatments for severe sickle cell disease, beta-thalassemia, glycogen storage disease, and other genetic conditions.

Use of Interest

Reporting Date Total Revenue Total Operating Expense Interest Income Interest Expense Interest Income Ratio Interest Expense Ratio
Sept. 30, 2024 $14.27m $108.65m - $-12127000.0 0.00% 11.16%
June 30, 2024 $11.77m $102.48m - $-14190000.0 0.00% 13.85%
March 31, 2024 $7.41m $99.69m - $-11849000.0 0.00% 11.89%

Company Impact

Help us evaluate Beam Therapeutics's impact from a halal perspective. Vote on the most significant aspect and submit any considerations that we may have missed.

Contribute

Recent News & Updates